Found: 11
Select item for more details and to access through your institution.
Acute aortic catastrophe caused by cardiovascular oncological manipulation by tyrosine kinase inhibitors with immune checkpoint blockades: a case report and literature review.
- Published in:
- European Heart Journal Case Reports, 2024, v. 8, n. 4, p. 1, doi. 10.1093/ehjcr/ytae169
- By:
- Publication type:
- Article
A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
- Published in:
- Familial Cancer, 2023, v. 22, n. 2, p. 135, doi. 10.1007/s10689-022-00313-0
- By:
- Publication type:
- Article
Apalutamide-Induced Toxic Epidermal Necrolysis in a Caucasian Patient with Metastatic Castration-Sensitive Prostate Cancer: A Case Report and Review of the Literature.
- Published in:
- Case Reports in Oncology, 2023, v. 16, n. 1, p. 652, doi. 10.1159/000532009
- By:
- Publication type:
- Article
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919864236
- By:
- Publication type:
- Article
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919864236
- By:
- Publication type:
- Article
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919864236
- By:
- Publication type:
- Article
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer--The GCIG Symptom Benefit Study.
- Published in:
- Oncologist, 2017, v. 22, n. 9, p. 1117, doi. 10.1634/theoncologist.2017-0047
- By:
- Publication type:
- Article
The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.
- Published in:
- Cancer Medicine, 2014, v. 3, n. 6, p. 1517, doi. 10.1002/cam4.302
- By:
- Publication type:
- Article
Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.
- Published in:
- Supportive Care in Cancer, 2014, v. 22, n. 5, p. 1417, doi. 10.1007/s00520-014-2148-9
- By:
- Publication type:
- Article